ライフサイエンスコーパス: rifabutin

1 R, 0.43; 95% CI, 0.27-0.69; P=.0003), versus rifabutin.

2 r azithromycin and $74000 per QALY saved for rifabutin.

3 25 microg/ml; ethambutol, 20 microg/ml; and rifabutin, 0.5 microg/ml.

4 s were susceptible to clarithromycin (100%), rifabutin (100%), ethambutol (92%), and sulfamethoxazole

5 The patients were assigned to receive rifabutin (300 mg daily), azithromycin (1200 mg weekly),

6 n and daily ethambutol (15 mg/kg/day), daily rifabutin (300 mg/day), and initial twice weekly (BIW) s

7 a combination of fluconazole, 200 mg/d, and rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 30

8 d rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 300 mg/d, for the final 2 weeks of the study.

9 romycin, TIW ethambutol (25 mg/kg/dose), TIW rifabutin (600 mg/dose), and initial BIW streptomycin.

10 infection at one year was 15.3 percent with rifabutin, 7.6 percent with azithromycin, and 2.8 percen

11 when two-drug prophylaxis was compared with rifabutin alone (hazard ratio, 0.28; P<0.001) or azithro

12 risk of developing PCP than those receiving rifabutin alone (n=236; p=0.008).

13 s (P=.06), and 11% for patients treated with rifabutin alone (P=.84).

14 he efficacy and safety of clarithromycin and rifabutin alone and in combination for prevention of Myc

15 7% of those randomized to clarithromycin or rifabutin alone or in combination, respectively; time-ad

16 Compared with rifabutin alone, hazard ratio for azithromycin was 0.54

17 7 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 24

18 ly azithromycin is more effective than daily rifabutin and infrequently selects for resistant isolate

19 increased the plasma concentrations of both rifabutin and LM565.

20 ntly increases the systemic exposure of both rifabutin and LM565.

21 ive (16%) of 31 isolates were susceptible to rifabutin and more than 90% were likely to be sensitive

22 We report 2.5 A resolution structures of rifabutin and rifapentin complexed with the Thermus ther

23 iotics, including two rifamycin derivatives, rifabutin and rifapentine, and streptolydigin and sorang

24 ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin,

25 ive randomised trial comparing azithromycin, rifabutin, and the two drugs in combination for preventi

26 Intermittent rifabutin-based therapy for HIV-related TB was well tole

27 nt (n = 1,075) and a study of a twice-weekly rifabutin-containing regimen for human immunodeficiency

28 Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 n

29 combination therapy were more effective than rifabutin for prevention of MAC disease, but combination

30 ndomized to receive 5 days of treatment with rifabutin, G-CSF, or both agents.

31 the azithromycin group was half that in the rifabutin group (hazard ratio, 0.53; P = 0.008).

32 ambutol hydrochloride, and streptomycin (and rifabutin, if sensitivity testing included it), and, if

33 he antimycobacterial drugs clarithromycin or rifabutin, induced a decrease in bacterial numbers that

34 ts associated with systemic corticosteroids, rifabutin-induced uveitis, cocaine-related retinal hemor

35 ntin, and contradictory to the steric model, rifabutin inhibits formation of the first and second pho

36 reated under direct supervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (give

37 rifabutin and the 25-desacetyl metabolite of rifabutin, LM565.

38 combination of amikacin, clarithromycin, and rifabutin may be the most efficacious therapy for the tr

39 either alone (n=233) or in combination with rifabutin (n=224), had a 45% lower risk of developing PC

40 Rifabutin plus azithromycin is even more effective but i

41 l program), followed by 4 mo of twice-weekly rifabutin plus isoniazid.

42 twice daily, ethambutol, rifampin (RMP), or rifabutin (RBT) and initial streptomycin, and they were

43 Rifabutin regimens should be restricted to patients who

44 This work focuses on the interaction of rifabutin (RFB), a naphthalenic ansamycin, with membrane

45 ryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01).

46 nfirmed that the binding sites for rifampin, rifabutin, rifapentine, and sorangicin A are shared, whe

47 ient improved with prolonged doxycycline and rifabutin treatment.

48 Rifabutin use was associated with a decreased relative r

49 e more likely to have histories of diarrhea, rifabutin use, or antifungal therapy.

50 54 (95% CI 0.32-0.94), for azithromycin plus rifabutin was 0.55 (0.32-0.94), and for regimens contain

51 Rifabutin was recommended in place of rifampin during tr

52 Clarithromycin and rifabutin were highly protective against development of

53 ss to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate, must be accelerated along w

54 eported in both the efficacy and toxicity of rifabutin with concomitant fluconazole therapy.